Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Evolocumab · 1 trial · 1 indication
Indication for intubation determined individually for each patient and clinical status
| Arm | Type | Description |
|---|---|---|
| PCSK9 inhibitor (evolocumab) | EXPERIMENTAL | 140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations |
| Usual Care | PLACEBO_COMPARATOR | 1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2. |
| Name | Type | Description |
|---|---|---|
| Evolocumab | DRUG | A single subcutaneous administration of 140 mg evolocumab |
| Saline solution | DRUG | A single subcutaneous injection of 1ml of 0,9% saline solution |
Inclusion Criteria: 1. Written informed consent for participation in the study 2. Male and female age 18 or more at the time of signing the informed consent 3. SARS-CoV-2 infection confirmed by Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 4. COVID-19 pneumonia with a typical r...
Top 20 of 30 competitors